Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PYGB | P11216 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285372 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL2429112 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL19603336 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL229613 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL3144972 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL4703623 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL8361874 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL22026379 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL22047951 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 | |
| SCHEMBL3144958 | 1.00 | SLC28A3 (0.50) | SLC28A3L3MBTL1MAPTPYGBLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110343155-B | Vaccinium myrtillus fruit acetylated anthocyanin specific transporter VcMATE2 | 吉林农业大学 | 2022-08-12 | — | — | CN | claimed |
| CN-102020681-A | Tetraacetyl talose compound and preparation method thereof | UNIV FUDAN | 2011-04-20 | — | — | CN | claimed |
| US-5561119-A | ANTITUMOR AGENTS | LABORATOIRES HOECHST (FR) | 1996-10-01 | — | — | US | claimed |
| WO-2024005461-A1 | NOVEL LINKER COMPOUND AND LIGAND-DRUG CONJUGATE THEREFOR | 주식회사 트리오어 | 2024-01-04 | — | — | WO | disclosed |
| WO-2024005460-A1 | COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME | 주식회사 트리오어 | 2024-01-04 | — | — | WO | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | TUMOREND, LLC (US) | 2022-12-15 | — | — | US | disclosed |
| CN-110343155-B | Vaccinium myrtillus fruit acetylated anthocyanin specific transporter VcMATE2 | 吉林农业大学 | 2022-08-12 | — | — | CN | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11203776-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | TUMOREND, LLC (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| EP-0560409-A2 | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation | ALBERTA RESEARCH COUNCIL (CA) | 1993-09-15 | — | — | EP | disclosed |
| US-5112739-A | Quinone-methide elimination | POLAROID CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| US-5079353-A | SIALIC ACID GLYCOSIDES, ANTIGENS, IMMUNOADSORBENTS, AND METHODS FOR THEIR PREPARATION | CHEMBIOMED, LTD. (CA) | 1992-01-07 | — | — | US | disclosed |
| US-5077200-A | Detection of hydrolyzing enzymes | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1991-12-31 | — | — | US | disclosed |
| EP-0396642-A1 | ENZYME CONTROLLED RELEASE SYSTEM. | POLAROID CORP (US) | 1990-11-14 | — | — | EP | disclosed |
| WO-1990001558-A1 | ENZYME CONTROLLED RELEASE SYSTEM | POLAROID CORPORATION (US) | 1990-02-22 | — | — | WO | disclosed |
| EP-0319253-A2 | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation | ALBERTA RESEARCH COUNCIL (CA) | 1989-06-07 | — | — | EP | disclosed |
| EP-0123485-A1 | Colon-specific prodrug, the preparation and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1984-10-31 | — | — | EP | disclosed |
| WO-1984004041-A1 | COLON-SPECIFIC DRUG DELIVERY SYSTEM | UNIV CALIFORNIA (US) | 1984-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | SIGLEC7, SIGLEC9, HAVCR2 | SLC28A3 2073/4885L3MBTL1 3179/4885MAPT 3680/4885 |
| US-11203776-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | SIGLEC7, SIGLEC9, HAVCR2 | SLC28A3 2073/4885L3MBTL1 3179/4885MAPT 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.